Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > March 6, 2024
Daily News
March 6, 2024
- Tsumura Sees 24% Price Hike as Kampo Enjoys Boon in FY2024 Revision: Poll
March 6, 2024
- Shionogi/Nagasaki University Enter New Phase of Malaria Collab, Aim for Clinical Trials
March 6, 2024
- Taisho’s Nonprescription Anti-Obesity Drug to Hit Pharmacy Shelves on April 8
March 6, 2024
- Mitsubishi, Daiichi Sankyo to Wind Up Diabetes Collab
March 6, 2024
- New Govt Forum for Fighting Drug Loss Should Devise Strategies for Honebuto: LDP Members
March 6, 2024
- Kyowa Pharma Joins Medipal-JWP JV, Now Sister Firm to Nichi-Iko
March 6, 2024
- Shionogi, FunPep Enter Option Deal for Pollen Allergy Vaccine
March 6, 2024
- Xocova Approval Meaningful, but Careful Use Should Continue: Minister
March 6, 2024
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…